AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02559804 — intervention group
Intervention type: OTHER
Intervention: survival and late effects
Description: survival and late effects
Study NCT02934100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Master 300
Description: Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching
Study NCT02934100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skanlab 25 BODYWAVE
Description: Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching
Study NCT02934100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVO US13 CosmoGamma
Description: Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching
Study NCT02934100 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LASER CTL1106MX
Description: Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
Study NCT03125616 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB Vaccine
Description: The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
Study NCT02079961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified yoghurt
Description: A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
Study NCT02079961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCC
Description: Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health.
Study NCT02079961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC
Description: Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health.
Study NCT04150848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion Regulation Therapy (GET)
Description: Six sessions delivered individually over 8 weeks
Study NCT04150848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Psychotherapy (ISP)
Description: Six sessions delivered individually over 8 weeks
Study NCT00387790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV
Study NCT00387790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo focal cranial radiotherapy
Study NCT01936441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia (CBT-I)
Description: See Experimental Arm Description
Study NCT01936441 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Menopause Education Control (MEC)
Description: See Experimental Arm Description
Study NCT00706303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported self management training and support
Description: Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
Study NCT00706303 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Supported self management training and support
Description: Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
Study NCT00737815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate: a total of 500 mg elemental magnesium
Description: 500 mg elemental magnesium
Study NCT00737815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo pill
Study NCT03658590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
Study NCT03658590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: a prefilled syringe with two milliliters of distilled water intravenously.
Study NCT03929380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squat protocol
Description: 60% of 1RM weight for 100 squat reps
Study NCT02840591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Study NCT02840591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Study NCT05326269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terbutaline
Description: Subcutaneous injection
Study NCT05326269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: Subcutaneous injection
Study NCT01043367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deprexil
Description: One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
Study NCT01043367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
Study NCT02110836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose ingestion
Description: Glucose ingestion during exercise at 1.8 g/min
Study NCT02110836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose ingestion
Description: Sucrose ingestion during exercise at 1.8 g/min
Study NCT01046838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 40 mg three times daily for 9 weeks
Study NCT01046838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet 3 times daily for 9 weeks
Study NCT01497288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFS (Intranasal Fentanyl Spray)
Description: Intranasal Fentanyl Spray
Study NCT03479164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra Low-Dose CT
Description: Ultra Low-Dose CT
Study NCT01719497 — intervention group
Intervention type: DRUG
Intervention: [C-11]OMAR
Description: PET radioligand
Study NCT03446196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid replacement based on MOSTCARE up
Description: Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
Study NCT04192383 — intervention group
Intervention type: RADIATION
Intervention: Cyberknife stereotactic radiosurgery
Description: Hypofractionated stereotactic radiosurgery
Study NCT02433951 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Maximal exercise test with ergospirometry.
Study NCT03134703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
Study NCT03134703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
Study NCT03110913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intakes
Description: Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
Study NCT02663713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 60mg twice daily
Study NCT02663713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 60mg twice daily
Study NCT02663713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily
Study NCT02663713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily
Study NCT02896413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
Study NCT02896413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 0.9% saline infusion
Study NCT04374942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
Study NCT04374942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
Study NCT03574012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Use Fitbit tracker
Study NCT03574012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Use Fitbit tracker
Study NCT03574012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
Study NCT03574012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive general health and fitness information from clinician
Study NCT03574012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03574012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05855148 — intervention group
Intervention type: PROCEDURE
Intervention: Enlistment For Lung Transplant
Description: All included patients are enlisted for lung transplantation
Study NCT04013685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orca-T
Description: an allogeneic stem cell and T-cell immunotherapy biologic
Study NCT03275350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Injectable Suspension
Description: Six monthly injections of extended-release naltrexone
Study NCT03275350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment for opioid use disorder provided at each HIV clinic
Study NCT02074410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762
Study NCT02074410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03828578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy
Description: High flow oxygen therapy delivered via Airvo2
Study NCT04504552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
Study NCT02191865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Soft gelatine capsule
Study NCT04335136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhACE2 APN01
Description: Patients will be treated with APN01 intravenously twice daily (BID).
Study NCT04335136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: Patients will be treated with placebo intravenously twice daily (BID).
Study NCT00787618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg Proellex
Description: Single dose
Study NCT00778661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin 400mg + clovalunic acid 57.5mg tablets
Study NCT00778661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin 400mg + clovalunic acid 57.5mg tablets
Study NCT02350478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
Study NCT02350478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive placebo orally once daily for 12 weeks.
Study NCT00311129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
Study NCT00311129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
Study NCT02354196 — intervention group
Intervention type: PROCEDURE
Intervention: CCTA
Description: CT of heart to assess coronary disease
Study NCT03171467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Study NCT04203186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone-proguanil
Description: Malaria standard treatment regimen
Study NCT01655004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
Study NCT04211909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet orally once daily.
Study NCT04211909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet orally once daily.
Study NCT01917162 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Soft contact lens CE-marked for daily disposable wear.
Study NCT01917162 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: UltraFilcon B contact lens
Description: Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
Study NCT00971152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: menotropins for injection
Description: comparison of different dosages
Study NCT00971152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropins for injection
Description: comparison of different dosages
Study NCT00971152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urofollitropin for injection
Description: comparison of different dosages
Study NCT00971152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urofollitropin for injection
Description: comparison of different dosages
Study NCT03348228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycitrate (HCA)
Description: Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
Study NCT03348228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxycitrate (HCA)
Description: Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
Study NCT00635297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous vertebroplasty
Description: PMMA injection 3-10 milliliter in each treated vertebrae
Study NCT00635297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: PMMA injection 3-10 milliliter in each treated vertebrae
Study NCT02180776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Summit 456 TLSO
Description: Thoracolumbarsacral orthosis